UPDATE: Piper Jaffray Raises Price Target on Thoratec to $33
According to Piper Jaffray, Thoratec (NASDAQ: THOR) price target is raised to $33.
Piper Jaffray said that it is incrementally more positive on Neutral-rated THOR after attending the HFSA convention in Boston. “We are increasing our price target to $33/share to reflect current Medtech multiples and our updated estimates.”
Thoratec closed yesterday at $30.43.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.